Glenmede Trust’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $14M | Sell |
18,059
-1
| -0% | -$766 | 0.07% | 245 |
|
|
2025
Q4 | $13.9M | Buy |
+18,060
| New | +$12.3M | 0.07% | 252 |
|
|
2025
Q1 | $25.6M | Buy |
40,332
+3,322
| +9% | +$2.28M | 0.14% | 140 |
|
|
2024
Q4 | $26.4M | Buy |
37,010
+30,915
| +507% | +$25.9M | 0.13% | 138 |
|
|
2024
Q3 | $6.41M | Sell |
6,095
-810
| -12% | -$901K | 0.03% | 419 |
|
|
2024
Q2 | $7.26M | Sell |
6,905
-50,935
| -88% | -$49.4M | 0.04% | 396 |
|
|
2024
Q1 | $55.7M | Sell |
57,840
-25,005
| -30% | -$23.8M | 0.28% | 89 |
|
|
2023
Q4 | $72.8M | Sell |
82,845
-1,913
| -2% | -$1.58M | 0.38% | 65 |
|
|
2023
Q3 | $69.8M | Buy |
84,758
+1,257
| +2% | +$988K | 0.4% | 60 |
|
|
2023
Q2 | $68.6M | Hold |
83,501
| – | – | 0.39% | 64 |
|
|
2023
Q1 | $68.6M | Sell |
83,501
-4,754
| -5% | -$3.59M | 0.39% | 64 |
|
|
2022
Q4 | $63.7M | Sell |
88,255
-4,753
| -5% | -$3.51M | 0.37% | 74 |
|
|
2022
Q3 | $64.1M | Sell |
93,008
-8,120
| -8% | -$5.11M | 0.4% | 63 |
|
|
2022
Q2 | $59.8M | Buy |
101,128
+1,395
| +1% | +$907K | 0.35% | 76 |
|
|
2022
Q1 | $69.7M | Buy |
99,733
+10,439
| +12% | +$6.6M | 0.34% | 75 |
|
|
2021
Q4 | $56.4M | Buy |
89,294
+596
| +0.7% | +$366K | 0.27% | 97 |
|
|
2021
Q3 | $53.7M | Sell |
88,698
-330
| -0.4% | -$205K | 0.28% | 92 |
|
|
2021
Q2 | $49.7M | Sell |
89,028
-2,313
| -3% | -$1.17M | 0.26% | 102 |
|
|
2021
Q1 | $43.2M | Sell |
91,341
-15,641
| -15% | -$7.62M | 0.23% | 116 |
|
|
2020
Q4 | $51.7M | Sell |
106,982
-2,191
| -2% | -$1.18M | 0.28% | 97 |
|
|
2020
Q3 | $61.1M | Sell |
109,173
-4,321
| -4% | -$2.62M | 0.37% | 78 |
|
|
2020
Q2 | $70.8M | Buy |
113,494
+3,557
| +3% | +$2.02M | 0.43% | 64 |
|
|
2020
Q1 | $41.3M | Hold |
109,937
| – | – | 0.19% | 152 |
|
|
2019
Q4 | $41.3M | Sell |
109,937
-102,807
| -48% | -$34.6M | 0.19% | 152 |
|
|
2019
Q3 | $59K | Sell |
212,744
-343
| -0.2% | -$101K | 0.27% | 102 |
|
|
2019
Q2 | $66.7K | Buy |
213,087
+162,979
| +325% | +$54.3M | 0.29% | 89 |
|
|
2019
Q1 | $20.6K | Buy |
50,108
+42,376
| +548% | +$17.4M | 0.09% | 297 |
|
|
2018
Q4 | $2.89K | Buy |
7,732
+315
| +4% | +$115K | 0.01% | 558 |
|
|
2018
Q3 | $3M | Buy |
7,417
+678
| +10% | +$258K | 0.01% | 567 |
|
|
2018
Q2 | $2.33M | Sell |
6,739
-280
| -4% | -$87.6K | 0.01% | 590 |
|
|
2018
Q1 | $2.64M | Hold |
7,019
| – | – | 0.01% | 610 |
|
|
2017
Q4 | $2.64M | Sell |
7,019
-22
| -0.3% | -$8.91K | 0.01% | 610 |
|
|
2017
Q3 | $3.15M | Sell |
7,041
-1,114
| -14% | -$530K | 0.01% | 571 |
|
|
2017
Q2 | $3.16M | Hold |
8,155
| – | – | 0.02% | 556 |
|
|
2017
Q1 | $3.16M | Sell |
8,155
-587
| -7% | -$218K | 0.02% | 556 |
|
|
2016
Q4 | $3.21M | Buy |
8,742
+2,203
| +34% | +$838K | 0.02% | 537 |
|
|
2016
Q3 | $2.63M | Buy |
6,539
+211
| +3% | +$84.6K | 0.01% | 578 |
|
|
2016
Q2 | $2.21M | Buy |
6,328
+825
| +15% | +$318K | 0.01% | 596 |
|
|
2016
Q1 | $1.98M | Sell |
5,503
-2,114
| -28% | -$871K | 0.01% | 613 |
|
|
2015
Q4 | $4.13M | Buy |
7,617
+1,001
| +15% | +$542K | 0.03% | 465 |
|
|
2015
Q3 | $3.08M | Buy |
6,616
+480
| +8% | +$258K | 0.02% | 496 |
|
|
2015
Q2 | $3.13M | Buy |
6,136
+613
| +11% | +$299K | 0.02% | 474 |
|
|
2015
Q1 | $2.49M | Buy |
5,523
+64
| +1% | +$27.1K | 0.02% | 543 |
|
|
2014
Q4 | $2.24M | Buy |
5,459
+105
| +2% | +$41.3K | 0.02% | 541 |
|
|
2014
Q3 | $1.93M | Buy |
5,354
+2,856
| +114% | +$957K | 0.02% | 558 |
|
|
2014
Q2 | $705K | Sell |
2,498
-267
| -10% | -$79.1K | 0.01% | 777 |
|
|
2014
Q1 | $830K | Buy |
2,765
+2,069
| +297% | +$637K | 0.01% | 745 |
|
|
2013
Q4 | $190K | Hold |
696
| – | – | ﹤0.01% | 1171 |
|
|
2013
Q3 | $217K | Buy |
696
+259
| +59% | +$68.1K | ﹤0.01% | 1100 |
|
|
2013
Q2 | $98K | Buy |
+437
| New | +$102K | ﹤0.01% | 1324 |
|
Other funds holding REGN
VCM
N
Glenmede Trust's REGN Position: Q1 2026 in Review
Glenmede Trust reduced its Regeneron Pharmaceuticals (REGN) stake by 0.01% in Q1 2026, selling an estimated $766 and leaving 18,059 shares worth $14M. The position accounts for 0.07% of the portfolio, ranked #245.
Glenmede Trust first reported a position in REGN in Q2 2013 and has held it in 50 quarters since. The position peaked at $72.8M in Q4 2023. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.
- Glenmede Trust held 18,059 shares of Regeneron Pharmaceuticals worth $14M as of Q1 2026.
- Glenmede Trust sold 1 Regeneron Pharmaceuticals share in Q1 2026, an estimated $766.
- Regeneron Pharmaceuticals made up 0.07% of Glenmede Trust's portfolio in Q1 2026, its #245 holding.
- Glenmede Trust first reported a position in Regeneron Pharmaceuticals in Q2 2013 and has held it in 50 quarters since.
- Glenmede Trust's Regeneron Pharmaceuticals position peaked at $72.8M in Q4 2023.
- 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.
Based on Glenmede Trust's 13F filing for Q1 2026, filed 26 May 2026.